Orexigen Therapeutics

Entry	Author	Date	Location
Third Rock Looks to Fight Fat in a New Way, With Ember Therapeutics	Luke Timmerman	12/15/11	Boston
Sofinnova Ventures Defies the Grim Mood, Raises $440M For Biotech-Only VC Fund	Luke Timmerman	10/17/11	San Francisco
Orexigen’s Diet Drug Springs Back to Life, Independa Gets $1.6M, NuVasive Faces Big Judgments in Patent Dispute, & More San Diego Life Sciences News	Bruce V. Bigelow	09/22/11	San Diego
Orexigen Revives Obesity Drug After One More Go-Round With FDA	Luke Timmerman	09/20/11	San Diego
Fearless Fantasy Football, Uh, I Mean Biotech, Predictions for the Season Ahead	Luke Timmerman	09/06/11	National
Zafgen Pockets $33M To Take Obesity Drug Through Next Big Step in Clinical Trials	Arlene Weintraub	07/07/11	Boston
Orexigen Halts U.S. Work on Weight Loss Drug, Illumina Cuts Price for Sequencing Patient Genomes, Ambit Pulls IPO, & More San Diego Life Sciences News	Bruce V. Bigelow	06/09/11	San Diego
Orexigen, Facing High Hurdle at FDA, Puts Obesity Drug Development on Hold; Shares Tank	Luke Timmerman	06/03/11	San Diego
FDA Approves Optimer Antibiotic, Amylin Wins Legal Round Against Lilly, Investors Excited by Orexigen Move, & More San Diego Life Sciences News	Bruce V. Bigelow	06/02/11	San Diego
Optimer Antibiotic Gets Panel Nod, CareFusion Buys Vestara, Tracon Raises $16.5M, & More San Diego Life Sciences News	Bruce V. Bigelow	04/07/11	San Diego
Illumina Rides Business Surge, IntegenX Acquires GenValult, Orexigen Cuts Payroll, & More San Diego Life Science News	Bruce V. Bigelow	02/10/11	San Diego
Orexigen Axes 40 Percent of Workforce After FDA Turns Down Obesity Drug	Luke Timmerman	02/09/11	San Diego
FDA Rejects Orexigen’s Weight-Loss Drug, Arena Lays Off 66, ResMed CEO Jumps to CareFusion, & More San Diego Life Sciences News	Bruce V. Bigelow	02/03/11	San Diego
Orexigen Fails to Win FDA Approval of Obesity Drug, Stock Crashes	Luke Timmerman	02/01/11	San Diego
San Diego’s Fight Against Diabesity: The Photo Gallery	Luke Timmerman	01/28/11	San Diego
Arena Pharmaceuticals Axes One-Fourth of Workforce As it Hangs On With Obesity Drug	Luke Timmerman	01/27/11	San Diego
Amylin Keeps Its Chin Up After A Rough 2010 With New Diabetes Drug	Luke Timmerman	01/21/11	San Diego
Zafgen Weight Loss Drug Shows Promise in First Human Test	Luke Timmerman	01/05/11	Boston
FDA Panel Recommends Orexigen’s Obesity Drug, Sequenom Raises Capital, CommNexus Reorganizes Its Free Incubator, & More San Diego Life Sciences News	Bruce V. Bigelow	12/09/10	San Diego
Orexigen Beats the Odds, Wins OK from FDA Panel for Obesity Drug	Luke Timmerman	12/07/10	San Diego
San Diego’s Fight Against Diabesity: Can Investors Make Money, and Can Startups Still Thrive?	Luke Timmerman	12/03/10	San Diego
The Fight Against Diabesity: How Will San Diego Adapt in the Era of Tough FDA Scrutiny?	Luke Timmerman	11/22/10	San Diego
Arena Obesity Drug Fails to Win FDA Approval, May Need More Clinical Testing	Luke Timmerman	10/25/10	San Diego
Arena Obesity Drug Was Effective by ‘Slim Margin,’ FDA Staff Raises Rat Cancer Concern; Shares Tumble	Luke Timmerman	09/14/10	San Diego
Zogenix Files for IPO, Orexigen Licenses Obesity Drug to Takeda, ImThera Raises Capital For Sleep Apnea, & More San Diego Life Science News	Bruce V. Bigelow	09/09/10	San Diego
Orexigen Nabs $1B Deal With Takeda to Market Obesity Drug, Shares Climb	Luke Timmerman	09/02/10	San Diego
Tethys Pockets $33M, Achaogen’s Vision for Antibiotics, Genentech Strikes Out at FDA Panel, & More Bay Area Life Sciences News	Luke Timmerman	07/23/10	San Francisco
Cypress Bio Gets Buyout Offer, Trius Prepares for IPO, Arena Gains Following Vivus Setback, & More San Diego Life Sciences News	Bruce V. Bigelow	07/22/10	San Diego
Euthymics, Led by Orexigen Vet, Nabs $24M for Depression Drug With Fewer Side Effects	Luke Timmerman	07/22/10	Boston
Lessons Learned About the Outlook for New Obesity Drug Approval	Tom Hughes	07/16/10	National
Page 1 of 3	next page »

Entry

Author

Date

Location

Third Rock Looks to Fight Fat in a New Way, With Ember Therapeutics

Luke Timmerman

12/15/11

Boston

Sofinnova Ventures Defies the Grim Mood, Raises $440M For Biotech-Only VC Fund

Luke Timmerman

10/17/11

San Francisco